ZLDPF Quote, Financials, Valuation and Earnings

Evaxion Biotech AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of -64.14%. Zealand Pharma AS's return on equity of -15.5% beat Evaxion Biotech AS's return on equity of --.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 674.9%. Given that Evaxion Biotech AS has higher upside potential than Zealand Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Evaxion Biotech AS quarterly revenues of $3M. Zealand Pharma AS's net income of -$47.3M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 0.54x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Galecto has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of --. Zealand Pharma AS's return on equity of -15.5% beat Galecto's return on equity of --.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Galecto has an analysts' consensus of $8.00 which suggests that it could grow by 160.59%. Given that Galecto has higher upside potential than Zealand Pharma AS, analysts believe Galecto is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.1M, which are larger than Galecto quarterly revenues of --. Zealand Pharma AS's net income of -$47.3M is lower than Galecto's net income of -$2.5M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

Genmab AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of 27.27%. Zealand Pharma AS's return on equity of -15.5% beat Genmab AS's return on equity of 22.23%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Genmab AS has an analysts' consensus of $29.31 which suggests that it could grow by 45.26%. Given that Genmab AS has higher upside potential than Zealand Pharma AS, analysts believe Genmab AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.676%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Genmab AS quarterly revenues of $715M. Zealand Pharma AS's net income of -$47.3M is lower than Genmab AS's net income of $195M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Genmab AS's PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 4.23x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of 37.18%. Zealand Pharma AS's return on equity of -15.5% beat Novo Nordisk AS's return on equity of 84.88%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 34.02%. Given that Novo Nordisk AS has higher upside potential than Zealand Pharma AS, analysts believe Novo Nordisk AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.41% to investors and pays a quarterly dividend of $1.10 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Zealand Pharma AS's net income of -$47.3M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 19.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 6.85x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.